Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9995180 | 0.86 | MCHR1 (0.47) | MCHR1CMA1KCNH2MAPTRXFP1 | |
| SCHEMBL941178 | 0.85 | MCHR1 (0.44) | MCHR1MAPTRXFP1 | |
| SCHEMBL12145799 | 0.83 | MCHR1 (0.61) | MCHR1 | |
| SCHEMBL12143932 | 0.83 | MCHR1 (0.52) | MCHR1KCNH2MAPTRXFP1 | |
| SCHEMBL12254026 | 0.82 | MCHR1 (0.48) | MCHR1CMA1MAPTRXFP1 | |
| SCHEMBL941150 | 0.81 | MCHR1 (0.47) | MCHR1MAPTRXFP1 | |
| Hydrochloric Acid SCHEMBL9995177 | 0.81 | MCHR1 (0.47) | MCHR1MAPTRXFP1 | |
| SCHEMBL12144362 | 0.80 | MCHR1 (0.45) | MCHR1CMA1KCNH2MAPTRXFP1 | |
| SCHEMBL12253942 | 0.79 | MCHR1 (0.46) | MCHR1CMA1KCNH2MAPTRXFP1 | |
| SCHEMBL12146312 | 0.79 | MCHR1 (0.45) | MCHR1CMA1KCNH2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067420-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MC1R, MCHR2 | MCHR1 1/4885CMA1 1154/4885PPARG 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.